Julie Gralow, MD


Phase 3 Trial Investigates T-DM1 and Pertuzumab in HER2+ Breast Cancer

Julie Gralow, MD, discusses the primary analysis of trastuzumab emtansine plus pertuzumab versus trastuzumab, pertuzumab, and taxane, after anthracyclines as adjuvant therapy in patients with high-risk HER2-positive early breast cancer in the of the KAITLIN study.

Julie Grisham


Targeted/Chemo Combo Effective in Preclinical pNETs Study

Combining the chemotherapy streptozotocin with various mTOR inhibitors was found to effectively target tumors in preclinical studies for pancreatic neuroendocrine tumors (pNETs).

Julie M. Vose, MD, MBA


Rationale for Genetic Testing in Patients With DLBCL

Julie M. Vose, MD, MBA, discusses the importance of conducting genetic testing on all patients with diffuse large B-cell lymphoma to better understand their disease and treat the disease properly.

Julie Nangia, MD


Getting Genetic Testing to Those Who Need It

Julie Nangia, MD, assistant professor of Medicine, Baylor College of Medicine, discusses getting genetic testing for patients. While the NCCN has guidelines of who should be tested, it may also be possible for physicians to write a letter of medical necessity for other people, such as Ashkenazi Jewish women, who have higher rates of BRCA mutations.

Julie R. Brahmer, MD


Sequencing Immunotherapy in Biomarker-Driven Advanced NSCLC

Julie Renee Brahmer, MD, MSc, discusses the issues with using tyrosine kinase inhibitors and immunotherapy in patients with locally advanced non–small cell lung cancer.

Julie R. Gralow, MD


Future Research Into Bisphosphonates in Breast Cancer

Julie R. Gralow, MD, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Care Center, University of Washington School of Medicine, discusses future research into bisphosphonates in breast cancer.

Jurgen Wolf, MD


GEOMETRY Study Confirms Importance of Testing for METex14 Alterations in Advanced NSCLC

Jurgen Wolf, MD, discusses the importance of broad genomic testing to identify alterations in patients with advanced non–small cell lung cancer (NSCLC). By identifying molecular alterations and driver mutations early on, patients can receive matched targeted therapies at a time in the course of disease when the treatments would have the greatest impact.

Justin F. Gainor, MD


Checkpoint Inhibitors Advance Standard of Care for Non-Small Cell Lung Cancer

Justin F. Gainor, MD, discusses the latest advancements with immune checkpoint inhibitors for the treatment of patients with non—small cell lung cancer.

Justin Taylor, MD


Phase II Evaluates Vemurafenib/Obinutuzumab in Hairy Cell Leukemia

Justin Taylor, MD, discusses the rationale for an ongoing phase II trial that is exploring the combination of vemurafenib, a BRAF inhibitor, plus the anti-CD20 monoclonal antibody obinutuzumab in previously untreated patients with classical hairy cell leukemia.

Jyoti D. Patel, MD, Northwestern University Robert H. Lurie Comprehensive Cancer Center


NSCLC: Factors in Selecting 2L Therapy After Progression on 1L ALK TKI

Expert perspectives on factors that aid in the selection of optimal therapy for patients with relapsed/refractory ALK+ non–small cell lung cancer.

Jyoti Patel, MD


NSCLC: Selecting a Frontline ALK-Targeted TKI Therapy

A panel of experts considers which factors best inform selection of first-line ALK TKI therapy in patients with non–small cell lung cancer.

Kabir Mody, MD


Expert Addresses Sequencing Challenges in HCC

Kabir Mody, MD, discusses the importance of understanding sequencing in patients with hepatocellular carcinoma.

Kamal Menghrajani, MD


Advances Changing the Treatment Landscape of AML

Kamal Menghrajani, MD, a hematologist/oncologist at Memorial Sloan Kettering Cancer Center, discusses the latest advancement in the research of acute myeloid leukemia. After treating this disease the same way with traditional chemotherapy for over 40 years, researchers have finally come to an understanding of what is happening in the AML cells, leading to a more precise treatment of these patients.

Kamana Misra, PhD


Researchers Analyze Karyotype Complexity and Prognosis in Acute Myeloid Leukemia

Diagnosis of acute myeloid leukemia (AML) is pivoted around cytogenetic analysis of patient bone marrow or peripheral blood cultures. The World Health Organization classification of tumors of the hematopoietic and lymphoid tissues is based on cytogenetic features along with other clinical, morphological, and immunophenotypic characteristics.

Kanti R. Rai, MD


Age-Related Recommendations in CLL Therapy

When treatment decisions are being made regarding chronic lymphocytic leukemia (CLL), patient age should be an important factor. CLL is a disease of the elderly, with more than 40% of all patients >75 years.

Kanti R. Rai, MD, Jacqueline C. Barrientos, MD


CLL in the Era of Targeted Therapies

Over the past few years, remarkable advances have been achieved in the field of CLL by rationally targeting pathways overexpressed and used by the malignant clone for proliferation and survival. These developments have been achieved by a better understanding of the underlying biology and the disease process.

Kanwal Raghav, MBBS, MD


Treatment Sequencing in Metastatic Colorectal Cancer

An expert breaks down therapy sequencing in metastatic colorectal cancer and provides some clinical pearls.

Karen L. Reckamp, MD


Limitations With Standard of Care in ICI-Pretreated Patients With NSCLC

Karen L. Reckamp, MD, discusses the current limitations with standard of care treatment for patients with non–small cell lung cancer.

Karen Reckamp, MD


Lung-MAP Trial of Pembrolizumab Plus Ramucirumab Improves Overall Survival in NSCLC

Karen L. Reckamp, MD, discusses the key findings of the phase 2 Lung-MAP substudy S1800A for patients with stage IV, previously-treated non–small cell lung cancer.

Karen Reckamp, MD, MS


Takeaways From Lung-MAP Substudy S1800A in NSCLC

Karen L. Reckamp, MD, MS, discusses findings from the phase 2 Lung-MAP substudy S1800A of pembrolizumab and ramucirumab in patients with stage IV, previously-treated non–small cell lung cancer.

Karim Fizazi, MD, PhD


Toxicities Associated With Talazoparib/Enzalutamide in HRR-Mutant mCRPC

Karim Fizazi, MD, discusses the toxicities seen with the combination of talazoparib plus enzalutamide.